Genetic regulation of ALK inhibitor response in diverse human cell types
Anaplastic lymphoma kinase (ALK) inhibitors are effective treatments for ALK-positive non-small cell lung cancer but cause diverse adverse events affecting multiple tissues. Genetic variation may contribute to inter-individual differences in susceptibility, but the small number of treated patients limits the power of genetic association studies. Moreover, the diversity of affected tissues and…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.